As I've said in the past, valuation often doesn’t matter in the short run, particularly for well-run companies offering above-average growth, but eventually, it does matter. Such has been the case with Boston Scientific Corporation ( BSX ) in 2025, as theAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not r ...